First-in-human dose-escalating study of ABSK043, a novel and oral small-molecule inhibitor of PD-L1, in patients with advanced solid tumors

被引：2
|
作者：
Cooper, A. [1 ]
Andelkovic, V. [2 ]
Wilkinson, K. [1 ]
Ganju, V. [3 ]
Lundy, J. [3 ]
Hong, M. [1 ]
Airey, S. [2 ]
Meng, L. L. [4 ]
Shen, B. [5 ]
Li, H. [6 ]
Yao, L. [7 ]
Zhang, M. [3 ,8 ]
Coward, J. [2 ]
机构：
[1] Liverpool Hosp, Dept Med Oncol, South Western Sydney Local Hlth Dist, Liverpool, NSW, Australia
[2] ICON Canc Ctr South Brisbane, Dept Gynaeoncol, Brisbane, Qld, Australia
[3] Peninsula & Southeast Oncol, Dept Oncol, Frankston, Vic, Australia
[4] Abbisko Therapeut Co Ltd, Med Clin, Shanghai, Peoples R China
[5] Abbisko Therapeut Co Ltd, Translat Med, Shanghai, Peoples R China
[6] Abbisko Therapeut Co Ltd, Biometr, Shanghai, Peoples R China
[7] Abbisko Therapeut Co Ltd, Clin Pharmacol, Shanghai, Peoples R China
[8] Abbisko Therapeut Co Ltd, Clin Dev, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1886
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
700P
引用
收藏
页码：S487 / S487
页数：1
相关论文
共 50 条
  • [1] Updated results of oral PD-L1 inhibitor ABSK043 in advanced solid tumor patients (pts) from a phase I study
    Yu, Y.
    Cooper, A.
    Coward, J.
    Zhang, J.
    Shu, Y.
    Zheng, T.
    Du, X.
    Chen, J.
    Xu, X.
    Li, Y.
    Zhang, S.
    Wang, X.
    Zhang, G.
    Chen, Y.
    Zhang, M.
    Yi, T.
    An, R.
    Fang, X.
    Lu, S.
    ANNALS OF ONCOLOGY, 2024, 35 : S1580 - S1580
  • [2] A first-in-human, phase I study of BPI-371153, a novel small-molecule PD-L1 inhibitor, in advanced solid tumors or recurrent/refractory (r/r) lymphoma
    Yang, J.
    Yu, Y.
    Ren, X.
    Zhong, D.
    Sun, M.
    Wen, Q.
    Du, X.
    Liu, X.
    Shen, Z.
    Li, P.
    Ding, L.
    Shi, Y-K.
    ANNALS OF ONCOLOGY, 2024, 35 : S1427 - S1427
  • [3] First-in-Human, Dose Escalation and Expansion Study of MT-6402 in Patients With PD-L1 Expressing Advanced Solid Tumors
    Spigel, D. R.
    Anand, B.
    Carroll, K.
    Dekker, J.
    Georgy, A.
    Hankins, S.
    Rethy, A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1102 - S1102
  • [4] A PHASE 1 STUDY EXPLORING THE SAFETY AND TOLERABILITY OF THE SMALL-MOLECULE PD-L1 INHIBITOR, INCB099318, IN PATIENTS WITH SELECT ADVANCED SOLID TUMORS
    Pinato, David
    Plummer, Ruth
    Gutierrez, Martin
    Yachnin, Jeffrey
    Schiza, Aglaia
    Hojgaard, Martin
    Smeland, Knut
    Edenfield, William
    Prenen, Hans
    Ny, Lars
    Anthoney, Alan
    Kotecki, Nuria
    Symeonides, Stefan
    Viviers, Louis
    Daniel, Jeannie
    Pulini, Jennifer
    Banerji, Udai
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A654 - A654
  • [5] A PHASE 1 STUDY EXPLORING THE SAFETY AND TOLERABILITY OF THE SMALL-MOLECULE PD-L1 INHIBITOR, INCB099280, IN PATIENTS WITH SELECT ADVANCED SOLID TUMORS
    Prenen, Hans
    Lesimple, Thierry
    Robert, Marie
    Delafontaine, Brant
    Machiels, Jean-Pascal
    Meniawy, Tarek
    Van Cutsem, Eric
    Kotecki, Nuria
    Piha-Paul, Sarina
    Schweizer, Michael
    Gadgeel, Shirish
    Daniel, Jeannie
    Viviers, Louis
    Howe, Jason
    Italiano, Antoine
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A766 - A766
  • [6] BROAD ANTI-TUMOR ACTIVITY OF A POTENT AND SELECTIVE SMALL MOLECULE ANTAGONIST OF PD-L1 ABSK043 IN COMBINATION WITH OTHER AGENTS IN PRECLINICAL MODELS
    Ying, Haiyan
    Zhang, Yongxian
    Yang, Fei
    Xin, Wenqun
    Wang, Jie
    Zhang, Jie
    Chen, Zhui
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A943 - A943
  • [7] First-in-human phase 1 dose-escalating trial of G305 in patients with advanced solid tumors expressing NY-ESO-1
    Amit Mahipal
    Samuel Ejadi
    Sacha Gnjatic
    Seunghee Kim-Schulze
    Hailing Lu
    Jan H. ter Meulen
    Richard Kenney
    Kunle Odunsi
    Cancer Immunology, Immunotherapy, 2019, 68 : 1211 - 1222
  • [8] First-in-human phase 1 dose-escalating trial of G305 in patients with advanced solid tumors expressing NY-ESO-1
    Mahipal, Amit
    Ejadi, Samuel
    Gnjatic, Sacha
    Kim-Schulze, Seunghee
    Lu, Hailing
    ter Meulen, Jan H.
    Kenney, Richard
    Odunsi, Kunle
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2019, 68 (07) : 1211 - 1222
  • [9] A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors
    Infante, Jeffrey R.
    Mendelson, David S.
    Burris, Howard A., III
    Bendell, Johanna C.
    Tolcher, Anthony W.
    Gordon, Michael S.
    Gillenwater, Heidi H.
    Arastu-Kapur, Shirin
    Wong, Hansen L.
    Papadopoulos, Kyriakos P.
    INVESTIGATIONAL NEW DRUGS, 2016, 34 (02) : 216 - 224
  • [10] A potent and selective small molecule antagonist of PD-L1 ABSK043 demonstrates significantanti-tumor efficacy in combination with other agents in preclinical models
    Ying, Haiyan
    Zhang, Yongxian
    Yang, Fei
    Xin, Wenqun
    Song, Jiaqi
    Chen, Zhui
    CANCER RESEARCH, 2022, 82 (12)
12345